Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna®, a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the closing of the previously announced underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $1.50 per share. The gross proceeds to Opexa from this offering were $18 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares in the offering were sold by Opexa. Opexa has also granted the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of common stock to cover over-allotments, if any. Opexa intends to use the net proceeds from the offering to fund further clinical development of Tcelna in an ongoing Phase IIb clinical study of patients with Secondary Progressive MS as well as the expenses of its operations during such development and for general corporate purposes. Opexa may also use a portion of the net proceeds to repay all or a portion of its outstanding convertible secured promissory notes. Aegis Capital Corp. acted as sole book-running manager for the offering. A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on August 7, 2013.The offering was made only by means of a prospectus.Copies of the prospectus relating to the offering are available on the SEC’s website at http://www.sec.gov.Copies of the prospectus may also be obtained from the offices of Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, via telephone at (212) 813-1010, or via email at email@example.com.This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.About Opexa Opexa’s mission is to lead the field of Precision Immunotherapy™ by aligning the interests of patients, employees and shareholders. The Company’s leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive MS. Tcelna is derived from T-cells isolated from the patient’s peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin.